Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Pte Ltd. Biolexis currently holds 22,982,529 shares of Outlook Therapeutics, Inc. (OTLK), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Pte Ltd. Biolexis has been a net neutral trader of OTLK stock. They have purchased $0 and sold $0 worth of shares.
Pte Ltd. Biolexis's most recent insider trade was on Apr 21, 2022, when they sold 27,982,529 shares at $0.00 per share.
Pte Ltd. Biolexis serves as Executive at Outlook Therapeutics, Inc. (OTLK). They have executed 4 insider transactions totaling $0 over their tenure at the company.
Pte Ltd. Biolexis holds the position of Executive at Outlook Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 8 years and currently hold a stake valued at $0.
Pte Ltd. Biolexis has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Pte Ltd. Biolexis was on Nov 7, 2018, when they purchased $8.0M worth of ONS shares. This transaction involved 8,577,248 shares at $0.93 per share.
Pte Ltd. Biolexis currently owns 22,982,529 shares of Outlook Therapeutics, Inc. (OTLK), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Pte Ltd. Biolexis's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Pte Ltd. Biolexis has 4 Form 4 filings on record as an insider at Outlook Therapeutics, Inc..
Set alerts for Pte Ltd. Biolexis and 40,000+ other insiders.